No Data
No Data
Hong Kong IPO dynamics: Today Jiuyuan Genetics, s.f. holding are in the subscription period
Gelonghui, November 21 | Today, Jiuyuan Gene (2566.HK) and s.f. holding (6936.HK) are in the subscription period, with no new stocks listed.
Zhito Hong Kong Stock Investment Journal | November 21
Hong Kong Stock Investment Log | November 21, 2024
insigma technology (600797.SH): Joint venture company Jiuyuan Gene plans to list on the main board of the Hong Kong Stock Exchange.
On November 20th, 2023, GeLongHui reported that insigma technology (600797.SH) announced that its wholly-owned subsidiary, Zhejiang Wangxin Technology Venture Capital Co., Ltd. (referred to as "Wangxin Venture Capital"), has a stake in Hangzhou Jiuyuan Gene Engineering Co., Ltd. (referred to as "Jiuyuan Gene"), which will disclose the prospectus on the Hong Kong Stock Exchange website on November 20, 2024, intending to conduct a global offering. The Hong Kong public offering portion consists of 4,540,000 shares of H shares (subject to reallocation), and the international placing portion consists of 40,858,800 shares of H shares (subject to reallocation and may be adjusted according to the exercise of the overallotment option), with the offer price.
Jiuyuan Gene has launched its initial public offering, bringing in seven cornerstone investors including Fosun, ali health, nanjing king-friend biochemical pharmaceutical, jointown pharmaceutical group, and is set to be listed in Hong Kong on November 28.
Jiuyuan Genomics launched its IPO, attracting cornerstone investors such as Fosun, Ali Health, Nanjing King-Friend Biochemical Pharmaceutical, Jointown Pharmaceutical Group, and 3 others, and will be listed in Hong Kong on November 28.
Hangzhou Jiuyuan Gene Engineering Co., Ltd. (02566.HK) new stock subscription.
Application method: (1) Contact your broker or call the comprehensive investment hotline at (852) 2270-2000, and please indicate your interest in subscribing for allocation or public offering of shares. (2) Subscribe for new shares through the Southbound Connect online trading platform.
Jiuyuan Gene (2566.HK) starts its initial public offering today with an entry fee of 2,537 Hong Kong dollars.
Gelonghui, November 20th | Jiuyuan Gene (2566.HK) is conducting an IPO from today until next Monday (25th), with an offering price of HKD 11.48-12.56 per share, releasing 45.3988 million shares, with 10% allocated for public offering in Hong Kong and the remainder for international placement, raising a maximum of HKD 0.57 billion. The minimum purchase is 200 shares, with an entry fee of HKD 2537.33. The stock is expected to be listed next Thursday (28th). The company has introduced 7 cornerstone investors, including subsidiaries of fosun pharma, and ali health's Hong Kong unit, with a total subscription amount of approximately HKD 0.35 billion. About 40% of the funds raised will be distributed.
No Data
No Data